Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 1.61% 126.00 122.00 130.00 126.00 126.00 126.00 24,568 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 195

Amryt Pharma Share Discussion Threads

Showing 4701 to 4714 of 5375 messages
Chat Pages: Latest  191  190  189  188  187  186  185  184  183  182  181  180  Older
DateSubjectAuthorDiscuss
17/6/2019
10:14
Yes, I agree with you Paps that we will just have to wait and see with regards to the outcome. However, I remain positive of the overall transaction... I am simply providing my opinion - which was requested here on this site. Based on my personal knowledge, I see the synergistic nature of the acquisition in terms of strengthening Amryt's pipeline and positioning in North America. With regards to MR MAD-LOSS - all I can say is that I agree with previous comments about you - you obviously have absolutely no conviction of the statements you are making, as evidenced by removal of your own postings!
diamondstar1
16/6/2019
21:15
mdalos1 16 Jun '19 - 16:32 - 4589 of 4589 0 0 0 Dim-Star... have you worked out how many shares in total will be in issue across the 3 Markets when the bigger, reformed Business re-enters those Markets ? Have you worked out how to associate the (spuriously framed) Valuations (two) of the combined Business to all of those Shares across those Markets ? Have you fathomed fully & properly what the 1:6 dilution to existing (UK) AIM Shareholders will actually mean taking the above into consideration fully & properly, i.e. what portion of the actual total shares in issue for the bigger, reformed Business across those Markets will be attributable to just AMRYT's current UK (pre 1:6) shares ? What portion of the possible combined Market valuation of the bigger, reformed Business will be attributable to the current UK AIM quoted Business ? Just hoping you've worked out the actual Facts & Figures, which hopefully underpin the positivity in your declarations ? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> The relisted share price all depends on how many shares are in issue following the relisting and at what price Joe Wiley can get the proposed US$60m placing away at. Until those facts are confirmed it's pointless speculating because AMYT is currently suspended so we can't sell if we are very bearish (like mdalos), or buy if we are very bullish (like Bermudashorts). Best NOT to speculate, IMO, since our shares are currently effectively valueless until they relist. Lets just wait and see what happens. We have to be patient because whether one is bearish, or bullish, over the contents of the RNS of 21st May we have no alternative. TINA (shades of Mrs Thatcher)! There Is No Alternative to being patient.
papillon
15/6/2019
23:52
Funny Papillon - that Mdalos used the term ‘Eejit’ - which suggests to me that he may be Irish, like Bronxville. We can always rely on Mdalos and Bronxville for their negative postings on Amryt, which is ironic given that Amryt is essentially an Irish Pharmaceutical company. Maybe Mdalos knows Bronxville, or perhaps they could even be the same person? I’m glad that Bronxville made a good call on Venn Life Sciences - I think Contract Research Organisations (CROs) have a major advantage of being based in Ireland - due to the favourable corporate tax rate of 12.5%.
diamondstar1
15/6/2019
21:59
Hi Alphabravo, I am extremely positive of the Aegerion transaction. For a long time now, I've written about the need for Amryt to in-license another product, and potentially look into partnering with another pharmaceutical company in USA in light of potential Episalvan approval in USA. They have effectively killed 2 birds with one stone with this move:- the big benefit is now having Metreleptin for both USA and EU markets, and also presence (and sales network) in North America. An added bonus is the targeted Nasdaq listing (which is now closer to reality) plus the fact that the suspension of Amryt share trading was actually well timed - I believe share price would have likely moved further downwards in the absence of positive news. Prior to the proposed Aegerion acquisition, Amryt shares were held mainly (about 65%) by institutions or large shareholders. For example, Software AG held 22.3% shares; AXA Framingham (9.8%), Cathal Friel (9.0%) and Joe Wiley (7.6%). I really do not think that these institutions/shareholders would allow their shareholding to be diluted (and total value reduced) with the Aegerion acquisition and recently announced 6 to 1 share consolidation. I think the diversification of the Amryt portfolio to include Metreleptin will clearly benefit Amryt - Metreleptin sales are growing at a steady rate and Aegerion had recently obtained Marketing authorization for Metreleptin in EU. This is compared to lomitapide which is facing price pressures due to alternative treatments in the dyslipidemia market e.g. PCSK-9 inhibitors. Finally, I think the 24p upside - if Episalvan meets key milestones for EB - is a fair compensation - given that the Amryt share price was down to 12.25p before share suspension. Moreover, my presumption is that the share price of the new company - will also stand to gain substantially - if marketing approval was obtained for Episalvan in EB.
diamondstar1
15/6/2019
16:52
Hey Diamondstar, whats your view on the Aegerion transaction? You seem to be in the expert in the room on Pharma
alphabravo321
15/6/2019
16:33
IOTA has not done so well so far in 2019. It's currently only marginally up on the price at the start of the year.
papillon
15/6/2019
16:27
Yes, I remember now, diamondstar. Many thanks.
papillon
15/6/2019
15:56
IOTA.... I think that was the Crypto the greendragon was very fond of.
diamondstar1
15/6/2019
11:03
O/T. I don't know if greendragon still follows this thread, but I know he was very keen on cryptocurrency. Bitcoin has done very well over the last 6 months. It's more than doubled in value since the start of 2019. I saw this Bloomberg article on another cryptocurrency that's doing even better. I remember that greendragon was keen on one particular cryptocurrency; not sure if it was Litecoin. hTTps://www.msn.com/en-gb/money/news/hottest-cryptocurrency-is-up-330percent-this-year-and-its-name-isnt-bitcoin/ar-AACUTP0?ocid=spartanntp
papillon
14/6/2019
18:03
mdalos1 - 14 Jun 2019 - 18:27:44 - 4579 of 4580 Amryt Pharma - AMYT Flutterby... you'll own 84% fewer Shares but the share price isn't going to be 6x higher !!! Then again... you're obviously not an actual Shareholder... just some deluded Eejit who re-posts other people's posts and then as an argument with your own post ??!!!! LOLs >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> ROFLMAO
papillon
14/6/2019
15:44
I thought you were going to stop posting unless there was something of use to say!
waterloo01
14/6/2019
15:37
"Everyone is entitled to shift their opinions: as John Maynard Keynes once put it, “When the facts change, I change my mind. What do you do, sir?” Until the facts change I trust that the RNS dated 21/5/2019 means that when AMYT eventually relists the share price will be significantly higher (as the RNS promises) than the suspension price. Of course the facts could change before AMYT relists. Of course I can't gamble on the facts staying the same, or changing, because of the suspension. I can only sit and twiddle my thumbs whilst mdalos posts his subjective opinions and figures non stop.
papillon
14/6/2019
15:07
mdalos1 - 14 Jun 2019 - 15:51:11 - 4574 of 4575 Amryt Pharma - AMYT WRONG WRONG AND WRONG I HAVE MY SHAREHOLDER COMMS PACK TO "GO ON"... BEING A BONAFIDE SHAREHOLDER. WHAT A BULL$H!TTE£ YOU ARE FLUTTERBY CLUELESS UNINFORMED HALFWIT AS EVER >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOLs. You've left your Caps Lock on. LOLs. You shouldn't have stopped taking your medication. How do you like being in Broadmoor?
papillon
13/6/2019
20:11
Before he deletes them! mdalos1 - 13 Jun 2019 - 18:59:43 - 4567 of 4568 Amryt Pharma - AMYT You happy with losing 66% of your large holding when the time comes then ABC-123 ? That sounds like a "large" 66% to me !! mdalos1 - 13 Jun 2019 - 18:02:04 - 4565 of 4568 Amryt Pharma - AMYT Another poor performance (worsening) to Dec 2018 6-12 months of the same and it would be raising large amounts via the begging bowl again. Conveniently the proposed takeover/acquisition/merger/reverse takeover will fill that begging bowl nicely but with existing UK AIM PIs diluted significantly. Expecting a further "Business Transformation" plan to be announced beyond the Business re-entering Markets. I think we could get seriously shafted :-(
papillon
Chat Pages: Latest  191  190  189  188  187  186  185  184  183  182  181  180  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200121 16:36:57